出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/08/05 22:28:31」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Differential expression of CART in feeding and reward circuits in binge eating rat model.
  • Bharne AP1, Borkar CD1, Subhedar NK2, Kokare DM3.
  • Behavioural brain research.Behav Brain Res.2015 Sep 15;291:219-31. doi: 10.1016/j.bbr.2015.05.030. Epub 2015 May 22.
  • Binge eating (BE) disrupts feeding and subverts reward mechanism. Since cocaine- and amphetamine-regulated transcript peptide (CART) mediates satiety as well as reward, its role in BE justifies investigation. To induce BE, rats were provided restricted access to high fat sweet palatable diet (HFSPD)
  • PMID 26008155
  • The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation.
  • Johnson A1, Neumann PH1, Peng J1, James J1, Russo V1, MacDonald H1, Gertzberg N1, Feleder C2.
  • Journal of neuroimmunology.J Neuroimmunol.2015 Sep 15;286:16-24. doi: 10.1016/j.jneuroim.2015.07.001. Epub 2015 Jul 6.
  • We investigated the role of intracerebroventricular (ICV) injection of rimonabant (500ng), a CB1 antagonist, on lipopolysaccharide ((LPS) 5mg/kg)-induced pulmonary inflammation in rats in an isolated perfused lung model. There were decreases in pulmonary capillary pressure (Ppc) and increases in the
  • PMID 26298320
  • Modulatory effects by CB1 receptors on rat spinal locomotor networks after sustained application of agonists or antagonists.
  • Veeraraghavan P1, Nistri A2.
  • Neuroscience.Neuroscience.2015 Sep 10;303:16-33. doi: 10.1016/j.neuroscience.2015.06.045. Epub 2015 Jun 27.
  • Sustained administration of cannabinoid agonists acting on neuronal CB1 receptors (CB1Rs) are proposed for treating spasticity and chronic pain. The impact of CB1Rs on mammalian locomotor networks remains, however, incompletely understood. To clarify how CB1Rs may control synaptic activity and locom
  • PMID 26126926


  • 薬物療法の現状と新規抗肥満薬開発への期待 (特集 肥満症 : 肥満症の最新知見) -- (肥満・肥満症の予防と治療)
  • Stimulatory and Inhibitory Roles of Brain 2-Arachidonoylglycerol in Bombesin-Induced Central Activation of Adrenomedullary Outflow in Rats
  • Shimizu Takahiro,Tanaka Kenjiro,Yokotani Kunihiko
  • Journal of Pharmacological Sciences 121(2), 157-171, 2013
  • … 2-AG-E (0.1 μmol/animal, i.c.v.) effectively reduced the bombesin (1 nmol/animal, i.c.v.)-induced elevation of plasma catecholamines with rimonabant (CB1 antagonist)-sensitive brain mechanisms. …
  • NAID 130003362679
  • エンドトキシン誘発腸管弛緩反応の作用機序-覚醒モルモットを用いた<I>in vivo</I>実験研究-
  • 二宮 宣文,根本 香代,久野 将宗
  • 日本救急医学会雑誌 23(8), 333-341, 2012
  • … 用いた薬物は,作動薬として内因性カンナビノイドのanandamide, 2-arachidonoilglycerol,阻害薬としてLPSを吸着するpolymyxin B固定化カラム,TLR4阻害薬であるTAK-242,CB1受容体阻害薬のAM281およびrimonabant,COX-2阻害薬のmeloxicamである。 …
  • NAID 130004542334


ジェネリックアコンプリア 新薬のダイエット医薬品アコンプリアのジェネリック薬 成分:Rimonabant 20mg 必ず医師の指導元ご使用下さい。 ジェネリックアコンプリアを1日1回、朝食の前に1錠(20mg)を服用してください ...
↑Topに戻る コメント (1) 仏サノフィ・アベンティス社は5日、Rimonabant(リモナバン)の全ての適応症における進行中の臨床試験を中止すると発表しました。 Sanofi-aventis to Discontinue all Clinical Trials with rimonabant (Press ...